UNCY Stock Overview
A biotechnology company, develops treatments for various medical conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Unicycive Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.68 |
| 52 Week High | US$1.82 |
| 52 Week Low | US$0.20 |
| Beta | 2.29 |
| 11 Month Change | 35.85% |
| 3 Month Change | 97.75% |
| 1 Year Change | 32.66% |
| 33 Year Change | -66.77% |
| 5 Year Change | n/a |
| Change since IPO | -88.41% |
Recent News & Updates
Recent updates
We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 21
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
Feb 16We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 18Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely
Mar 08Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats
Sep 07Unicycive Therapeutics GAAP EPS of -$0.24
Aug 16Unicycive inks licensing deal for kidney disease drug Renazorb in Asia
Jul 18Shareholder Returns
| UNCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 33.1% | 4.3% | 1.6% |
| 1Y | 32.7% | 18.8% | 32.3% |
Return vs Industry: UNCY exceeded the US Biotechs industry which returned 18% over the past year.
Return vs Market: UNCY matched the US Market which returned 32.4% over the past year.
Price Volatility
| UNCY volatility | |
|---|---|
| UNCY Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UNCY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: UNCY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 14 | Shalabh Gupta | unicycive.com |
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte.
Unicycive Therapeutics, Inc. Fundamentals Summary
| UNCY fundamental statistics | |
|---|---|
| Market cap | US$61.25m |
| Earnings (TTM) | -US$24.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs UNCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNCY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.10m |
| Earnings | -US$24.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did UNCY perform over the long term?
See historical performance and comparison